EraCal Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $1.01M

  • Investors
  • 7

EraCal Therapeutics General Information

Description

Developer of drugs in-vivo screening platform designed to treat metabolic syndrome with medical advancements. The company's platform develops drugs including identified appetite-suppressors that are selective to food intake, do not provide neuronal side-effects, and significantly outperform current anti-obesity agents in potency and in selectivity, enabling patients to suppress appetite and lose body weight.

Contact Information

Website
www.eracal.ch
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Aeschengraben 13
  • 4051 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Aeschengraben 13
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EraCal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Seed Round 16-Oct-2019 $1.01M Completed Generating Revenue
6. Seed Round 16-Jan-2019 Completed Generating Revenue
5. Grant 01-Jan-2019 Completed Generating Revenue
4. Grant 13-Jun-2018 Completed Generating Revenue
3. Grant 20-Mar-2018 Completed Generating Revenue
2. Grant 01-Jan-2017 $293.79 Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view EraCal Therapeutics’s complete valuation and funding history, request access »

EraCal Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
Preference
To view EraCal Therapeutics’s complete cap table history, request access »

EraCal Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs in-vivo screening platform designed to treat metabolic syndrome with medical advancements. The compan
Drug Discovery
Basel, Switzerland
4 As of 2026

Campbell, CA
 

Copenhagen, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EraCal Therapeutics Competitors (9)

One of EraCal Therapeutics’s 9 competitors is Vivus, a Corporate Backed or Acquired company based in Campbell, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vivus Corporate Backed or Acquired Campbell, CA
Antag Therapeutics Venture Capital-Backed Copenhagen, Denmark
Sernova Biotherapeutics Corporation Mississauga, Canada
HemoShear Therapeutics Venture Capital-Backed Charlottesville, VA
Gelesis Formerly VC-backed Calimera, Italy
You’re viewing 5 of 9 competitors. Get the full list »

EraCal Therapeutics Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

EraCal Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026037494-A1 New compounds and their uses Pending 14-Aug-2024
WO-2022053541-A1 Compounds for use as appetite suppressant Inactive 10-Sep-2020

EraCal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EraCal Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bernina BioInvest Venture Capital Minority
EFI Lake Geneva Ventures Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
Redalpine Venture Capital Minority
UZH Lifesciences Fund Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

EraCal Therapeutics FAQs

  • When was EraCal Therapeutics founded?

    EraCal Therapeutics was founded in 2017.

  • Where is EraCal Therapeutics headquartered?

    EraCal Therapeutics is headquartered in Basel, Switzerland.

  • What is the size of EraCal Therapeutics?

    EraCal Therapeutics has 4 total employees.

  • What industry is EraCal Therapeutics in?

    EraCal Therapeutics’s primary industry is Drug Discovery.

  • Is EraCal Therapeutics a private or public company?

    EraCal Therapeutics is a Private company.

  • What is the current valuation of EraCal Therapeutics?

    The current valuation of EraCal Therapeutics is .

  • What is EraCal Therapeutics’s current revenue?

    The current revenue for EraCal Therapeutics is .

  • How much funding has EraCal Therapeutics raised over time?

    EraCal Therapeutics has raised $1.11M.

  • Who are EraCal Therapeutics’s investors?

    Bernina BioInvest, EFI Lake Geneva Ventures, Novartis Venture Fund, Redalpine, and UZH Lifesciences Fund are 5 of 7 investors who have invested in EraCal Therapeutics.

  • Who are EraCal Therapeutics’s competitors?

    Vivus, Antag Therapeutics, Sernova Biotherapeutics, HemoShear Therapeutics, and Gelesis are some of the 9 competitors of EraCal Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process